Hypothyroidism After the TAVI Procedure in Elderly Patients

Aortic stenosis is highly prevalent in advancing age. The prognosis of this disease has dramatically changed with the surgical replacement of the aortic valve and the trans catheter aortic valve re-placement (TAVI). The TAVI procedure is also successful in octogenarians and frail patients. However, the evaluation before the TAVI procedure requires a high dosage of iodinated contrast agent with, consequently, an increased risk for thyroid dysfunction. The primary endpoint of this study is to assess, prospectively, the incidence and the predictive factors (underlying thyroid disease, medication, food preservative, topical antiseptics) of hypothyroidism after a TAVI procedure. The secondary endpoint is the influence of the occurrence of hypothyroidism after the TAVI procedure on the geriatric assessment.

Study Overview

• Status: Recruiting
• Conditions: Hypothyroidism; TAVI
• Intervention / Treatment: Diagnostic test: Assesment of thyroïd function

Detailed Description

Aortic stenosis is highly prevalent in advancing age. The prevalence is 2.5% at an age of 75 years and 8.1% at an age of 85 years. The estimated mortality after onset of symptoms (dizziness, syncope, thoracic pain and dyspnea) with conventional medical treatment is 75% after 3 years follow up. The prognosis of this disease has dramatically changed with the surgical replacement of the aortic valve. However, an open surgical procedure is not always possible in high risk patients for anatomical reasons (sternotomy, radiation and chest deformation) or comorbidities defined by the Euroscore and the Society of Thoracic Surgeons' risk score (STS score).

Trans-catheter aortic valve replacement (TAVI) is becoming the standard care of patients suffering of non-operable, high risk severe and symptomatic aortic stenosis. The TAVI procedure is associated with immediate hemodynamic improvement characterized by a decreased aortic valve mean pressure gradient, an improved left ventricular end systolic volume and mass, a decreased end ventricular diastolic volume and a better ejection fraction. This hemodynamic improvement translates into better clinical outcomes. Mortality rates (2.2% and 6.7% at one month and at one year) and long term stroke rate are similar after TAVI or surgical replacement.

The TAVI procedure is also successful in octogenarian and in frail patients. Consequently, patient's frailty is a growing argument to refer the patient for a percutaneous treatment of valve disease instead of a conventional surgical approach.

The standard evaluation before the TAVI procedure comprises some radiologic studies with iodinated contrast agent (coronarography, thoracic CT scanner and the TAVI procedure itself). Furthermore, some patients require a treatment with Amiodarone® because of the occurrence of atrial fibrillation during the procedure.

A typical iodinated contrast study confers 13500 µg of free iodine and 15-60g of bound iodine (several hundred thousand times above the recommended daily intake). An excess of iodium expo-sure can lead to thyroid dysfunction:

• Hyperthyroidism particularly in patients with underlying nodular thyroid disease (Jod-Basedow effect).
• Hypothyroidism in patients with underlying thyroid disease or in patients who are taking medication (lithium, amiodarone) which can lead to thyroid dysfunction. The mechanism of iodinated contrast agent hypothyroidism is the failure to escape of the acute Wolf-Chaikoff effect.

Amiodarone confers 3-21 mg iodine daily and can also lead to thyroid dysfunction particularly in patients with underlying thyroid disease because of the failure to escape of the acute Wolf-Chaikoff effect. An autoimmune mechanism is also described.

Epidemiology In our recent clinical practice (geriatric day hospital UZ Brussel), an increased incidence of hypothyroidism in elderly patients after a TAVI procedure has been observed. In our knowledge, there are no data about the incidence of hypothyroidism and what could be the impact for elderly patients after a TAVI procedure.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Bert Bravenboer, Dr, PhD; Phone Number: 9512 024749512; Email: bert.Bravenboer@uzbrussel.be
• Study Contact Backup: Name: nathalie Compté, Dr, PhD; Phone Number: 9159 024749159; Email: nath_compte@hotmail.com

Study Locations

• Belgium
  • Brussel, Belgium, 1090
    • Recruiting
    • UZ Brussel
    • Contact: Nathalie Compté, PhD; Phone Number: 9159 024749159; Email: nath_compte@hotmail.com
    • Contact: Bert Bravenboer, PhD; Phone Number: 9512 024749512; Email: bert.bravenboer@uzbrussel.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 70 years and older (Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Provision of signed and dated, written Informed Consent prior to any study specific proce-dures
• Patient: males and females must be ≥ 70 years old
• Patients who will undergo a TAVI procedure

Exclusion Criteria:

• - No obtained signed, dated and written Informed Consent.
• Known thyroid dysfunction (for example: Basedow, Hashimoto,...)
• Patients receiving any of the following: Lithium, Strumazol or a recent treatment of radio-Iode

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Patient underwent TAVI procedure; - Elderly patients who will undergo a TAVI procedure coming to the geriatric day hospital	Diagnostic test: Assesment of thyroïd function; Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
to assess prospectively the incidence of hypothyroidism after a TAVI procedure.	Change is value of TSH and fT4,	Baseline, at 4-8-12 weeks
To assess the underlying thyroid disease	Presence of thyroid nodule door ultra sound	At baseline
To assess the influence of iodinated constrast on hypothyroidism	Value of presence of Iodine in urine sample	At 4 weeks
To assess the influence of autoimmune disease on hypothyroidism after TAVI	Anti TPO	Baseline
To assess the influence of presence of antibodies on hypothyroidism after TAVI	Anti TG	Baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on dependence level	Value of dependance through : - Katz scale (ADL: assessment of activities of daily living): It rates 6 tasks of daily liv-ing (bathing, dressing, toilet, transfer, continence and eating) on a scale from 1 to 4. A low score means absence of dependence, and a high score the maximum of de-pendence for the task	Baseline and at 1 month
to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on the cognitive function	Value of MMSE (Mini Mental Status Examination): a 0-30 score of cognitive func-tions,<25/30 meaning cognitive function impairment	Baseline and at 1 month
to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on depression	Value of GDS (geriatric depression scale) a 0-15 score. A score > 15 means risk for depression	Baseline and at 1 month
to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on mobility	Value of mobility through; Tinetti : a 0-28 score : a score < 26 means mobility problems; Timed up and go : Impaired mobility if > 12.5s; 4 meter walking speed : risico for sarcopenia if speed > 0.7m/s	Baseline and at 1 month
to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on instrumental daily living	- lawton scale (assessment of instrumentary assessment of activities of daily living) a 0-27 score; a high score means independence; a low score means dependence	Baseline and at 1 month

Collaborators and Investigators

• Sponsor: Universitair Ziekenhuis Brussel

Publications and helpful links

General Publications

• Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB; PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012 May 3;366(18):1686-95. doi: 10.1056/NEJMoa1200384. Epub 2012 Mar 26.
• Stone ML, Kern JA, Sade RM. Transcatheter aortic valve replacement: clinical aspects and ethical considerations. Ann Thorac Surg. 2012 Dec;94(6):1791-5. doi: 10.1016/j.athoracsur.2012.09.047. No abstract available.
• Leontyev S, Walther T, Borger MA, Lehmann S, Funkat AK, Rastan A, Kempfert J, Falk V, Mohr FW. Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. Ann Thorac Surg. 2009 May;87(5):1440-5. doi: 10.1016/j.athoracsur.2009.01.057.
• Leung AM, Braverman LE. Iodine-induced thyroid dysfunction. Curr Opin Endocrinol Diabetes Obes. 2012 Oct;19(5):414-9. doi: 10.1097/MED.0b013e3283565bb2.
• Trohman RG, Sharma PS, McAninch EA, Bianco AC. Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. Trends Cardiovasc Med. 2019 Jul;29(5):285-295. doi: 10.1016/j.tcm.2018.09.005. Epub 2018 Sep 20.

Study record dates

Study Major Dates

• Study Start (Actual): July 26, 2021
• Primary Completion (Estimated): December 31, 2050
• Study Completion (Estimated): December 31, 2050

Study Registration Dates

• First Submitted: March 19, 2021
• First Submitted That Met QC Criteria: April 2, 2021
• First Posted (Actual): April 5, 2021

Study Record Updates

• Last Update Posted (Actual): December 9, 2024
• Last Update Submitted That Met QC Criteria: December 4, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Hypothyroidism; TAVI
• Additional Relevant MeSH Terms: Endocrine System Diseases; Thyroid Diseases; Hypothyroidism
• Other Study ID Numbers: UZCompte3

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: no sharing plan

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No